Xerava
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Eravacycline
- Made by
- PAION Pharma GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | PAION Pharma GmbH |
|---|---|
| Active substance | Eravacycline |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J01AA13 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2018-09-20 |
| Last updated by the regulator | 2026-03-13 |
| EMA product number | EMEA/H/C/004237 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).